Critical Illness Endocrine Response: Two Phases Requiring Different Treatment Approaches
The neuroendocrine response to critical illness has two distinct phases — an acute beneficial activation followed by a chronic harmful suppression — and treatment must match the phase for optimal outcomes.
Quick Facts
What This Study Found
The neuroendocrine response to critical illness is biphasic (acute activation → chronic suppression), and therapeutic intervention must be phase-appropriate: GH secretagogues/TRH benefit the chronic phase but acute-phase augmentation may be harmful.
Key Numbers
How They Did This
Clinical review integrating neuroendocrine profiling data from critically ill patients with clinical trial outcomes, including the negative GH replacement trial and positive GH secretagogue studies.
Why This Research Matters
Timing is everything in ICU endocrine therapy. This review explains why the same therapy (GH augmentation) can save lives in chronic illness but kill patients in acute illness.
The Bigger Picture
ICU medicine increasingly recognizes that critical illness is not a static state — it evolves through distinct phases requiring different treatments. Endocrine therapy must be matched to the disease phase for safety.
What This Study Doesn't Tell Us
Review based on available clinical data through 2001. Optimal timing of GH secretagogue therapy not precisely defined.
Questions This Raises
- ?How do clinicians determine which phase a patient is in?
- ?Could biomarkers guide phase-appropriate endocrine therapy?
- ?Should all prolonged ICU patients receive GH secretagogue assessment?
Trust & Context
- Key Stat:
- Phase matters Augmenting hormones in acute illness can be harmful, but restoring them in chronic suppression can be life-saving — timing determines whether treatment helps or hurts
- Evidence Grade:
- Moderate evidence from a clinical review integrating biphasic physiology with trial outcomes, providing a coherent therapeutic framework.
- Study Age:
- Published in 2001 by the Leuven group. The biphasic model has been refined and remains the dominant framework for understanding ICU neuroendocrine dysfunction.
- Original Title:
- The neuroendocrine response to stress is a dynamic process.
- Published In:
- Best practice & research. Clinical endocrinology & metabolism, 15(4), 405-19 (2001)
- Authors:
- Van den Berghe, G(10)
- Database ID:
- RPEP-00703
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Why does treatment timing matter in the ICU?
Early in critical illness, the body's hormone surge is protective. Boosting hormones further can be dangerous (this is what the failed GH trial showed). But weeks later, hormones become suppressed, and restoring them with GH secretagogues can help recovery.
How do doctors know which phase a patient is in?
Generally, the acute phase lasts hours to days, and the chronic suppression phase begins after several days in the ICU. Hormone levels and clinical trajectory help determine the appropriate timing for intervention.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00703APA
Van den Berghe, G. (2001). The neuroendocrine response to stress is a dynamic process.. Best practice & research. Clinical endocrinology & metabolism, 15(4), 405-19.
MLA
Van den Berghe, G. "The neuroendocrine response to stress is a dynamic process.." Best practice & research. Clinical endocrinology & metabolism, 2001.
RethinkPeptides
RethinkPeptides Research Database. "The neuroendocrine response to stress is a dynamic process." RPEP-00703. Retrieved from https://rethinkpeptides.com/research/van-2001-the-neuroendocrine-response-to
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.